Daniel O'Day (AP Images)
Amid remdesivir craze Gilead finds time for another oncology pact — looping in all things NK cells
Gilead’s $4.9 billion buyout of Forty Seven, announced in early March, landed in a different era before the pandemic consumed biopharma news. But even amid …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.